Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial
2016 ESMO Congress
Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses study findings on chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (Abstract LBA37)
Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)
Katja Weisel, MD, of the University of Tübingen, discusses in German study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the importance of tumor location, and its implications for treatment, in right-sided and left-sided metastatic colon cancer.